Breast Cancer Pathology in the Era of Genomics

Hannah Y Wen; Laura C Collins

doi:10.1016/j.hoc.2022.08.004

Breast Cancer Pathology in the Era of Genomics

Hematol Oncol Clin North Am. 2023 Feb;37(1):33-50. doi: 10.1016/j.hoc.2022.08.004.

Authors

Hannah Y Wen¹, Laura C Collins²

Affiliations

¹ Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: weny@mskcc.org.
² Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: lcollins@bidmc.harvard.edu.

PMID: 36435613
DOI: 10.1016/j.hoc.2022.08.004

Abstract

The era of genomic medicine provides an opportunity for pathologists to offer greater detail about the molecular underpinnings of a patient's cancer and thereby more targeted therapeutic options. In this review article, the role of genomics in breast cancer pathology is discussed, as it pertains to risk management, classification of special tumor types, predictive and prognostic testing, identification of actionable therapeutic targets, and monitoring for disease progression or development of treatment resistance.

Keywords: Breast cancer; Germline testing; Ki67; Multigene assay; Mutation profiling; PD-L1; Special histologic subtype; ctDNA.

Publication types

Review
Research Support, N.I.H., Extramural

MeSH terms

Breast Neoplasms* / genetics
Breast Neoplasms* / pathology
Breast Neoplasms* / therapy
Female
Genomics
Humans
Precision Medicine
Prognosis

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States